What Boston's pre-seed investors actually back
Boston's pre-seed list isn't dominated by one sector the way you might expect from a biotech town. B2B and enterprise software show up most often among the city's pre-seed investors, and information technology isn't far behind. Health care, biotechnology, and wellness round out a strong second tier, which tracks with Boston's reputation as a life sciences hub, but it's not the whole story if you're building something outside health care.
Venture capitalists make up the largest single group in the mix, and angel individuals aren't far behind. A meaningful share also carry the private equity investor tag on AngelMatch, worth noting that tag applies to individuals here, not investment firms, alongside a smaller group of founders who've since turned around and started writing checks themselves.
If you're building a health tech or biotech company, you're pitching into the deepest and most competitive part of this pool. If you're building B2B software, you actually have more investors to choose from, just spread across a less obviously "Boston" narrative. Once you've got some traction, the pool gets a lot bigger too; Boston's seed investors list runs several times deeper than the pre-seed one.
Cambridge still owns the earliest stage, even as Boston pulls ahead on dollars
Here's something that doesn't show up on a generic Boston page: within Greater Boston, where you're actually headquartered still matters at pre-seed. Cambridge, anchored by MIT, Harvard, and the teaching hospitals along the Longwood corridor, has long been the default landing spot for the earliest, most academic spinouts. Boston proper, particularly the Seaport and the suburbs further out, has become where those companies go once they've raised past the first round and need more space and a lower cost base.
The dollars back this up. Massachusetts biopharma companies, a big slice of what Boston's pre-seed pool backs, raised roughly $6.85 billion in venture money in 2025, and for the second year running, Boston-headquartered companies out-raised Cambridge-headquartered ones, taking in about $2.1 billion versus Cambridge's roughly $1.95 billion. That's a shift in the center of gravity toward growth-stage capital, not a sign Cambridge is closing to newcomers. If your company hasn't spun out of a lab yet, don't assume Cambridge is off limits just because Boston's dollar totals are catching up. It just means the split between the two is less predictable than it used to be.
What to bring to a first meeting with a Boston pre-seed investor
Boston pre-seed investors, especially the ones connected to the health care and biotech scene, tend to ask harder technical questions earlier than investors in other cities. You don't need a fully baked clinical or regulatory plan at pre-seed, but you do need to show you understand where the hard problems actually are, not just the ones that are easy to explain in a pitch deck. Vague answers about "FDA strategy" or "go-to-market" land worse here than in a city with a thinner technical bench sitting across the table.
Team matters more than traction at this stage, and Boston investors lean on that even harder than most, because so many of them came up through the same research institutions and know how to evaluate a founding team's actual depth. If you or a co-founder came out of MIT, Harvard, or one of the teaching hospitals, say so early and specifically; the network effects here are real and investors will check.
Since you're likely talking to more investors here than you can track in your head, especially once you widen the search past the city itself, it's worth keeping notes on who said what and when in a fundraising CRM so you're not repeating yourself or missing a follow-up window.
What a Boston pre-seed check actually looks like
Across AngelMatch, angel checks run $25,000 to $500,000, and that range holds in Boston too, whether the investor is a solo angel or one of the smaller funds that write pre-seed-sized checks. The venture capitalists in Boston's pre-seed pool mostly write bigger checks once a company graduates to seed or Series A, in the $2 million to $100 million or more range, but a handful will do smaller pre-seed checks, especially if they've already met the founder through the local network.
Expect dilution in the usual range for an early round, around 15% to 25%, regardless of whether your lead is a Boston angel or an out-of-town investor. Boston's pool also overlaps heavily with the wider Massachusetts investor base, so if you're not finding the right fit in the city alone, widening to the state opens up meaningfully more options.
Timing your outreach around Boston's calendar
Boston runs on an academic and conference calendar more than most startup cities. Late August, when a lot of the research institutions are between semesters, is a quiet stretch for the biotech-adjacent investors in particular. The last two weeks of December are slow across the board, same as most places, but January usually picks back up fast here because so many of Boston's health care and biotech investors travel for the big industry conference season and come back with fresh mandates to deploy.
If you're outreaching cold rather than through a warm intro, personalize each note to the specific investor's actual focus area rather than sending the same email to everyone on a list. It's a small thing, but in a market this dense, generic outreach gets noticed for the wrong reason. A tool that tracks opens and replies can help you see which version of your pitch is actually landing before you've burned through your whole list, and you can build that into your outreach workflow directly.
Boston's pre-seed pool is bigger and more varied than its biotech reputation suggests, so don't narrow your search to health care investors just because that's the city's best-known story. Start with the investors whose stated focus actually matches what you're building, lean on warm intros wherever the local academic network gives you one, and keep your list moving in an investor database built to filter by exactly this kind of overlap.
Pre-seed investors
